MarketWatch (press release) Galvus� (vildagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral diabetes medications that enhance the body's natural ability to control blood sugar. The Galvus� (vildagliptin) safety and efficacy profile has been established in a ... and more »
Family Practice News Digital Network ... and showed a nonsignificant trend toward a higher risk for colorectal cancer (CRC). No association was noted between CRC and thiazolidinedione (TZD), Dr. Siddharth Singh reported at the annual Digestive Disease Week. ... There was considerable ... and more »
pharmabiz.com The Zydus Group has announced a breakthrough in its research efforts with Lipaglyn (Saroglitazar), a novel drug targeted at bridging an unmet healthcare need for treating diabetic dyslipidemia or hypertriglyceridemia in type II diabetes, not controlled ...
Family Practice News Digital Network A reanalysis of data from a controversial cardiovascular safety study of rosiglitazone was well-conducted and provided results that ...
MarketWatch (press release) Galvus� (vildagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral diabetes medications that enhance the body's natural ability to control blood sugar. The Galvus� (vildagliptin) safety and efficacy profile has been established in a ... and more »
Family Practice News Digital Network ... and showed a nonsignificant trend toward a higher risk for colorectal cancer (CRC). No association was noted between CRC and thiazolidinedione (TZD), Dr. Siddharth Singh reported at the annual Digestive Disease Week. ... There was considerable ... and more »
Pharmacy Europe NICE recommends the use of dapagliflozin as a treatment option for adults with Type 2 diabetes as dual therapy in combination with metformin, and in combination with insulin with or without other oral antidiabetic drugs .(1) Currently in the UK, more ... and more »
PMLiVE GlaxoSmithKline's (GSK) controversial type II diabetes drug Avandia (rosiglitazone) has had its marketing authorisation suspended in Europe and is to be marketed under a restricted access programme in the US. ... outweigh the risks', while the US Food ...
